Nanox Expands U.S. Footprint with NuvioDx Distribution Deal

Event summary

  • Nanox Impact Inc. signed a distribution agreement with NuvioDx LLC on May 4, 2026 to deploy Nanox.ARC systems across U.S. clinical sites.
  • NuvioDx will support the deployment of Nanox.ARC multi-source digital tomosynthesis systems in various states.
  • The Nanox.ARC is an FDA-cleared system offering 3D imaging at lower cost and reduced radiation dose compared to traditional CT.
  • This agreement follows Nanox’s 2026 strategy to build a diversified distribution network in the U.S.

The big picture

Nanox’s deal with NuvioDx underscores its push to expand beyond traditional hospital settings, aligning with broader trends in decentralized healthcare delivery. The agreement strengthens Nanox’s U.S. commercialization strategy, but success hinges on seamless integration with NuvioDx’s operational capabilities and sustained utilization across clinical sites.

What we're watching

Market Adoption
How NuvioDx’s regional expertise will accelerate Nanox.ARC’s clinical adoption in the U.S.
Competitive Positioning
Whether Nanox can sustain its cost and radiation advantages against traditional CT systems.
Execution Risk
The pace at which Nanox scales its U.S. distribution network amid competitive pressures.